Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Karam, Sana D ^a   Horne, Zachary D ^a   Hong, Robert L ^a,b   McRae, Don ^b   Duhamel, David ^b   Nasr, Nadim M ^a,b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b VIRGINIA HOSPITAL CENTER   (United States)

Author keywords

Age; Boost; Cyberknife; Dose escalation; Locally advanced; Nodal; SABR; SBRT; Stage IIIA; Stage IIIB

Indexed keywords

STEROID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COUGHING; DISEASE COURSE; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEMOPTYSIS; HOSPITALIZATION; HUMAN; INTERSTITIAL PNEUMONIA; LOCALLY ADVANCED NON SMALL CELL LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PNEUMONIA; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION PNEUMONIA; RECURRENT DISEASE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; STEROID THERAPY; THORAX PAIN; TREATMENT PLANNING; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FIDUCIAL MARKER; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIOMETRY; RADIOSURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FIDUCIAL MARKERS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOMETRY; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84880012263     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-179     Document Type: Article

References (26)

1. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17(9):2692-2699.
2. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. Concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer 2011, 103(19):1452-1460. PMCID: 3186782.
3. Nguyen NP, Bishop M, Borok TJ, Welsh J, Hamilton R, Cohen D, et al. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res 2010, 30(3):953-961.
4. Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117(2):358-364. 10.1378/chest.117.2.358, 10669675.
5. Moreno-Jimenez M, Aristu J, Lopez-Picazo JM, Ramos LI, Gurpide A, Gomez-Iturriaga A, et al. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. Radiother Oncol 2008, 88(3):342-350. 10.1016/j.radonc.2008.05.019, 18558448.
6. Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007, 30(3):239-244. 10.1097/01.coc.0000256691.27796.24, 17551299.
7. Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010, 77(2):367-372. PMCID: 2869096, 10.1016/j.ijrobp.2009.04.029, 2869096, 20457350.
8. Bradley JD PR, Komaki R, et al. Randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy ± cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 2011, https://www.astro.org/Meetings-and-Events/2011-Annual-Meeting/Index.aspx.
9. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 2008, 34(8):719-727. 10.1016/j.ctrv.2008.06.001, 18657910.
10. Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S155-S160. PMCID: 2854159, 2854159, 20171512.
11. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 2010, 37(8):4078-4101. 10.1118/1.3438081, 20879569.
12. Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM. Residual (1)(8)F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 2012, 83(4):e551-e555. 10.1016/j.ijrobp.2012.01.012, 22417800.
13. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012, 83(5):1558-1565. PMCID: 3474601, 10.1016/j.ijrobp.2011.10.035, 3474601, 22572078.
14. Timmerman RD. Surgery versus stereotactic body radiation therapy for early-stage lung cancer: who's down for the count?. J Clin Oncol 2010, 28(6):907-909. 10.1200/JCO.2009.26.5165, 20065172.
15. Nakayama H, Satoh H, Kurishima K, Ishikawa H, Tokuuye K. High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2010, 78(3):645-650. 10.1016/j.ijrobp.2009.08.037, 20869582.
16. Salazar OM, Sandhu TS, Lattin PB, Chang JH, Lee CK, Groshko GA, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int J Radiat Oncol Biol Phys 2008, 72(3):707-715. 10.1016/j.ijrobp.2008.01.054, 18455322.
17. Hepel JT, Peter J, Hiatt JR, Patel S, Osibanjo O, Safran H, et al. Dosimetric feasibility of dose escalation using SBRT boost for stage III Non-small cell lung cancer. Front Oncol. 2012, 2:124. PMCID: 3458262, 3458262, 23057009.
18. Hoffmann AL, Troost EG, Huizenga H, Kaanders JH, Bussink J. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial. Int J Radiat Oncol Biol Phys 2012, 83(5):1596-1602. 10.1016/j.ijrobp.2011.10.032, 22245206.
19. Arvidson NB, Mehta MP, Tome WA. Dose coverage beyond the gross tumor volume for various stereotactic body radiotherapy planning techniques reporting similar control rates for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72(5):1597-1603. 10.1016/j.ijrobp.2008.07.048, 19028283.
20. De Ruysscher D, Nestle U, Jeraj R, Macmanus M. PET scans in radiotherapy planning of lung cancer. Lung Cancer 2012, 75(2):141-145. 10.1016/j.lungcan.2011.07.018, 21920625.
21. Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2013, 85(5):1325-1331. 10.1016/j.ijrobp.2012.11.011, 23265574.
22. De Ruysscher D, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Utama I, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005, 62(4):988-94. 10.1016/j.ijrobp.2004.12.019, 15989999.
23. Gillham C, Zips D, Ponisch F, Evers C, Enghardt W, Abolmaali N, et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol 2008, 88(3):335-41. 10.1016/j.radonc.2008.05.004, 18514339.
24. Iwasaki A, Shirakusa T, Miyoshi T, Hamada T, Enatsu S, Maekawa S, et al. Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease. Thorac Cardiovasc Surg 2006, 54(1):42-6. 10.1055/s-2005-865828, 16485188.
25. Machtay M, Paulus R, Moughan J, Komaki R, Bradley J, Choy H, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma: a radiation therapy oncology group analysis. J Thorac Oncol 2012, 7(4):716-722. 10.1097/JTO.0b013e3182429682, 22425920.
26. 0516 GCC Stereotactic Body Radiation Therapy As A Boost After Definitive Treatment With Concurrent Chemoradiation In Patients With Non-Small Cell Lung Cancer http://www.clinicaltrialsgps.com/search-clinical-trials/trial-12642/#sthash.hwNfjoX0.dpuf, 0516 GCC.